Lexeo Therapeutics (LXEO) EBIAT (2022 - 2026)

Lexeo Therapeutics' EBIAT history runs 5 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• In Q1 2026, EBIAT rose 38.16% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at -$87.6 million (up 19.88% YoY), while the FY2025 annual figure was -$100.0 million, down 1.7% from the prior year.
• EBIAT came in at -$20.2 million for Q1 2026 at Lexeo Therapeutics, up from -$21.0 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of -$13.4 million in Q2 2023 to a low of -$32.7 million in Q1 2025.
• A 5-year average of -$21.1 million and a median of -$20.3 million in 2025 frame the typical range for EBIAT.
• Across the five-year window, EBIAT plunged 82.65% in 2024 and surged 38.16% in 2026, its largest moves.
• Lexeo Therapeutics' EBIAT stood at -$14.6 million in 2022, then grew by 2.79% to -$14.2 million in 2023, then sank by 82.65% to -$25.9 million in 2024, then grew by 18.99% to -$21.0 million in 2025, then rose by 3.83% to -$20.2 million in 2026.
• According to Business Quant data, EBIAT over the past three periods registered -$20.2 million, -$21.0 million, and -$20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison